Gsa Capital Partners LLP Pliant Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$14.58 - $20.15 $664,658 - $918,578	45,587 New	45,587 $790,000
Q1 2023 May 12, 2023	SELL	$18.73 - $36.26 $19,722 - $38,181	-1,053 Reduced 5.2%	19,206 $510,000
Q4 2022 Feb 13, 2023	SELL	$17.0 - $25.43 $33,592 - $50,249	-1,976 Reduced 8.89%	20,259 $392,000
Q3 2022 Nov 14, 2022	SELL	$7.67 - $24.23 $389,774 - $1.23 Million	-50,818 Reduced 69.56%	22,235 $464,000
Q2 2022 Aug 09, 2022	BUY	$4.11 - $8.75 $19,797 - $42,148	4,817 Added 7.06%	73,053 $585,000
Q1 2022 May 11, 2022	BUY	$7.01 - $14.1 $67,597 - $135,966	9,643 Added 16.46%	68,236 $478,000
Q4 2021 Feb 14, 2022	BUY	$12.27 - $18.26 $401,548 - $597,576	32,726 Added 126.52%	58,593 $791,000
Q3 2021 Nov 12, 2021	BUY	$16.48 - $28.98 $426,288 - $749,625	25,867 New	25,867 $437,000

168

63.2M

245K

373K

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $600M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.